S&P 500   3,369.26 (-0.32%)
DOW   29,232.70 (-0.56%)
QQQ   234.37 (-0.12%)
AAPL   318.48 (-1.99%)
FB   217.17 (+1.40%)
MSFT   186.82 (+0.79%)
AMZN   2,143.15 (+0.39%)
CGC   22.07 (-0.27%)
NVDA   290.19 (+0.14%)
BABA   219.34 (-0.13%)
MU   57.49 (-1.73%)
GE   12.85 (+0.16%)
TSLA   853.58 (+6.69%)
AMD   56.62 (+2.37%)
T   38.20 (-0.13%)
ACB   1.57 (-0.63%)
F   8.08 (-0.25%)
NFLX   387.45 (+1.85%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.38 (-0.83%)
S&P 500   3,369.26 (-0.32%)
DOW   29,232.70 (-0.56%)
QQQ   234.37 (-0.12%)
AAPL   318.48 (-1.99%)
FB   217.17 (+1.40%)
MSFT   186.82 (+0.79%)
AMZN   2,143.15 (+0.39%)
CGC   22.07 (-0.27%)
NVDA   290.19 (+0.14%)
BABA   219.34 (-0.13%)
MU   57.49 (-1.73%)
GE   12.85 (+0.16%)
TSLA   853.58 (+6.69%)
AMD   56.62 (+2.37%)
T   38.20 (-0.13%)
ACB   1.57 (-0.63%)
F   8.08 (-0.25%)
NFLX   387.45 (+1.85%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.38 (-0.83%)
S&P 500   3,369.26 (-0.32%)
DOW   29,232.70 (-0.56%)
QQQ   234.37 (-0.12%)
AAPL   318.48 (-1.99%)
FB   217.17 (+1.40%)
MSFT   186.82 (+0.79%)
AMZN   2,143.15 (+0.39%)
CGC   22.07 (-0.27%)
NVDA   290.19 (+0.14%)
BABA   219.34 (-0.13%)
MU   57.49 (-1.73%)
GE   12.85 (+0.16%)
TSLA   853.58 (+6.69%)
AMD   56.62 (+2.37%)
T   38.20 (-0.13%)
ACB   1.57 (-0.63%)
F   8.08 (-0.25%)
NFLX   387.45 (+1.85%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.38 (-0.83%)
S&P 500   3,369.26 (-0.32%)
DOW   29,232.70 (-0.56%)
QQQ   234.37 (-0.12%)
AAPL   318.48 (-1.99%)
FB   217.17 (+1.40%)
MSFT   186.82 (+0.79%)
AMZN   2,143.15 (+0.39%)
CGC   22.07 (-0.27%)
NVDA   290.19 (+0.14%)
BABA   219.34 (-0.13%)
MU   57.49 (-1.73%)
GE   12.85 (+0.16%)
TSLA   853.58 (+6.69%)
AMD   56.62 (+2.37%)
T   38.20 (-0.13%)
ACB   1.57 (-0.63%)
F   8.08 (-0.25%)
NFLX   387.45 (+1.85%)
PRI   134.85 (-1.45%)
BAC   34.36 (-1.41%)
DIS   138.38 (-0.83%)
Log in

NASDAQ:ADLR - Adolor Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin). In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ADLR
CUSIPN/A
Phone+1-302-6587581

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ADLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ADLR and its competitors with MarketBeat's FREE daily newsletter.


Adolor (NASDAQ:ADLR) Frequently Asked Questions

What is Adolor's stock symbol?

Adolor trades on the NASDAQ under the ticker symbol "ADLR."

Has Adolor been receiving favorable news coverage?

News coverage about ADLR stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Adolor earned a coverage optimism score of -5.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Adolor.

What is Adolor's official website?

The official website for Adolor is http://www.adolor.com/.

How can I contact Adolor?

Adolor's mailing address is 700 Pennsylvania Dr, EXTON, PA 19341-1129, United States. The biopharmaceutical company can be reached via phone at +1-302-6587581.


MarketBeat Community Rating for Adolor (NASDAQ ADLR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about Adolor and other stocks. Vote "Outperform" if you believe ADLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Golden Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel